TOP - Daily
Minocycline, given before the start of treatment with cetuximab and chemoradiotherapy, plus topical pimecrolimus as needed, can reduce the severity of cetuximab-induced skin toxicity in patients with non–small-cell lung cancer (NSCLC), according to researchers from The Netherlands.
Arsenic trioxide (As2O3) improves survival of patients with acute promyelocytic leukemia (APL) when delivered immediately after induction therapy, according to a new study from researchers with Cancer and Leukemia Group B (Blood. November 11, 2010. Epub ahead of print).
Men treated with long-term androgen deprivation therapy (ADT) for prostate cancer are at increased risk for colorectal cancer, according to a study released in the Journal of the National Cancer Institute.
Denosumab delayed or prevented skeletal-related events (SREs) better than zoledronic acid, according to a study comparing the two agents in patients with breast cancer and bone metastases.
The prognosis for patients with biliary tract cancer is poor, and no standard palliative care has been defined. Now Austrian researchers report that adding cetuximab to gemcitabine and oxaliplatin (GEMOX) for patients with advanced biliary tract cancer results in a high overall response rate and good disease control and is well tolerated.
Age is an important factor when considering tamoxifen therapy for older women with early-stage breast cancer, according to a large retrospective study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology. The findings indicate that older women treated with conservative surgery and radiation therapy (CS + RT) derive only limited benefit from tamoxifen.
Patients with chronic lymphocytic leukemia (CLL) who have insufficient levels of vitamin D at the time of diagnosis are at greater risk of cancer progression and death than patients with adequate levels, Mayo Clinic researchers have found.
A large National Cancer Institute (NCI)–sponsored study has shown for the first time that a screening method can reduce deaths from lung cancer by detecting cancers at relatively early stages.
Use of aspirin or other anticoagulants in addition to radiation therapy or surgery may reduce the risk of dying of prostate cancer by more than half, according to a large study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology.
Treatment with a combination of hormone therapy and radiation therapy (RT) improves overall and disease-specific survival in men with locally advanced prostate cancer compared with hormone therapy alone, according to interim results of a study presented at the 52nd Annual Meeting of the American Society for Radiation Oncology.